|
"j�nne p a"的相关文件
显示项目 1-4 / 4 (共1页)
1
每页显示[10|25|50]项目
| 國立成功大學 |
2023 |
Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET-Amplified Non–Small Cell Lung Cancer: TATTON
|
Hartmaier, R.J.;Markovets, A.A.;Ahn, M.J.;Sequist, L.V.;Han, J.-Y.;Cho, B.C.;Yu, H.A.;Kim, S.-W.;Yang, J.C.-H.;Lee, J.-S.;Su, W.-C.;Kowalski, D.M.;Orlov, S.;Ren, S.;Frewer, P.;Ou, X.;Cross, D.A.E.;Kurian, N.;Cantarini, M.;J�nne, P.A. |
| 國立成功大學 |
2022 |
Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
|
Wang, M.;Yang, J.C.-H.;Mitchell, P.L.;Fang, J.;Camidge, D.R.;Nian, W.;Chiu, Chiu C.-H.;Zhou, J.;Zhao, Y.;Su, W.-C.;Yang, T.-Y.;Zhu, V.W.;Millward, Millward M.;Fan, Y.;Huang, W.-T.;Cheng, Y.;Jiang, L.;Brungs, D.;Bazhenova, L.;Lee, C.K.;Gao, B.;Xu, Y.;Hsu, W.-H.;Zheng, L.;J�nne, P.A. |
| 國立成功大學 |
2022 |
Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor– Resistant, EGFR-Mutated Non–Small Cell Lung Cancer
|
J�nne, P.A.;Baik, C.;Su, W.-C.;Johnson, M.L.;Hayashi, Hayashi H.;Nishio, M.;Kim, D.-W.;Koczywas, M.;Gold, K.A.;Steuer, C.E.;Murakami, H.;Yang, J.C.-H.;Kim, S.-W.;Vigliotti, M.;Shi, R.;Qi, Z.;Qiu, Y.;Zhao, L.;Sternberg, D.;Yu, C.;Yu, H.A. |
| 國立成功大學 |
2017 |
Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial
|
Thress, K.S.;Jacobs, V.;Angell, H.K.;Yang, J.C.-H.;Sequist, L.V.;Blackhall, F.;Su, W.-C.;Schuler, M.;Wolf, J.;Gold, K.A.;Cantarini, M.;Barrett, J.C.;J�nne, P.A. |
显示项目 1-4 / 4 (共1页)
1
每页显示[10|25|50]项目
|
